Dare Bioscience (DARE) Competitors $2.04 -0.04 (-1.92%) Closing price 04:00 PM EasternExtended Trading$2.04 +0.00 (+0.25%) As of 05:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DARE vs. OTLK, ASRT, IGMS, PYXS, FBRX, JMAC, WHWK, STRO, IRD, and VNRXShould you be buying Dare Bioscience stock or one of its competitors? The main competitors of Dare Bioscience include Oncobiologics (OTLK), Assertio (ASRT), IGM Biosciences (IGMS), Pyxis Oncology (PYXS), Forte Biosciences (FBRX), Maxpro Capital Acquisition (JMAC), Whitehawk Therapeutics (WHWK), Sutro Biopharma (STRO), Opus Genetics (IRD), and VolitionRx (VNRX). These companies are all part of the "pharmaceutical products" industry. Dare Bioscience vs. Its Competitors Oncobiologics Assertio IGM Biosciences Pyxis Oncology Forte Biosciences Maxpro Capital Acquisition Whitehawk Therapeutics Sutro Biopharma Opus Genetics VolitionRx Oncobiologics (NASDAQ:OTLK) and Dare Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership. Which has more risk & volatility, OTLK or DARE? Oncobiologics has a beta of 0.26, suggesting that its share price is 74% less volatile than the S&P 500. Comparatively, Dare Bioscience has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Which has stronger valuation and earnings, OTLK or DARE? Dare Bioscience has lower revenue, but higher earnings than Oncobiologics. Oncobiologics is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncobiologics$1.51M79.67-$75.37M-$0.57-4.74Dare Bioscience$10K2,749.92-$4.05M-$2.14-0.95 Does the media refer more to OTLK or DARE? In the previous week, Dare Bioscience had 4 more articles in the media than Oncobiologics. MarketBeat recorded 17 mentions for Dare Bioscience and 13 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 1.12 beat Dare Bioscience's score of 0.63 indicating that Oncobiologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncobiologics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dare Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in OTLK or DARE? 11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are held by institutional investors. 4.8% of Oncobiologics shares are held by insiders. Comparatively, 4.8% of Dare Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is OTLK or DARE more profitable? Company Net Margins Return on Equity Return on Assets OncobiologicsN/A N/A -332.30% Dare Bioscience N/A N/A -103.70% Do analysts rate OTLK or DARE? Oncobiologics presently has a consensus price target of $9.60, suggesting a potential upside of 255.56%. Dare Bioscience has a consensus price target of $12.00, suggesting a potential upside of 488.24%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Dare Bioscience is more favorable than Oncobiologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncobiologics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Dare Bioscience 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryDare Bioscience beats Oncobiologics on 8 of the 13 factors compared between the two stocks. Get Dare Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for DARE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DARE vs. The Competition Export to ExcelMetricDare BioscienceMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.50M$3.09B$5.74B$9.77BDividend YieldN/A2.24%4.40%4.08%P/E Ratio-0.9520.7830.4126.04Price / Sales2,749.92347.65428.97104.72Price / CashN/A43.2325.7828.79Price / Book-2.969.809.706.08Net Income-$4.05M-$54.08M$3.27B$265.64M7 Day Performance0.99%4.93%3.94%3.11%1 Month Performance-20.62%3.64%3.81%0.39%1 Year Performance-42.05%8.20%31.26%18.52% Dare Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DAREDare Bioscience2.4928 of 5 stars$2.04-1.9%$12.00+488.2%-41.4%$27.50M$10K-0.9530OTLKOncobiologics2.3124 of 5 stars$2.77+18.4%$9.60+246.6%-60.6%$78.55MN/A-4.8620Positive NewsGap UpHigh Trading VolumeASRTAssertio1.9977 of 5 stars$0.81-0.4%$2.38+193.2%-38.6%$78.25M$124.96M-1.8020IGMSIGM Biosciences4.2585 of 5 stars$1.27flat$5.50+333.1%N/A$76.57M$145.05M-1.41190PYXSPyxis Oncology2.2757 of 5 stars$1.24+0.8%$8.67+598.9%-62.5%$76.20M$16.15M-0.7760Positive NewsAnalyst UpgradeFBRXForte Biosciences2.7253 of 5 stars$11.91+2.9%$68.00+470.9%+89,208.3%$76.17MN/A-0.735Gap UpHigh Trading VolumeJMACMaxpro Capital AcquisitionN/A$5.67-4.1%N/A+4,280.1%$76.14MN/A0.002,021News CoverageGap UpWHWKWhitehawk TherapeuticsN/A$1.61+0.6%N/AN/A$75.40M$25.98M-26.8340High Trading VolumeSTROSutro Biopharma4.061 of 5 stars$0.91+3.6%$4.47+390.8%-83.3%$74.43M$62.04M-0.36240News CoverageIRDOpus Genetics1.8279 of 5 stars$1.15-4.2%$7.33+537.7%N/A$71.89M$15.42M-0.6014Gap UpVNRXVolitionRx2.101 of 5 stars$0.68-1.7%$3.50+412.4%+14.5%$71.03M$1.31M-1.9080 Related Companies and Tools Related Companies Oncobiologics Alternatives Assertio Alternatives IGM Biosciences Alternatives Pyxis Oncology Alternatives Forte Biosciences Alternatives Maxpro Capital Acquisition Alternatives Whitehawk Therapeutics Alternatives Sutro Biopharma Alternatives Opus Genetics Alternatives VolitionRx Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DARE) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dare Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dare Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access